Business Context and Reporting Period
Company: GSK plc
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: December 12, 2025
Subject: Announcement of a positive Committee for Medicinal Products for Human Use (CHMP) opinion from the European Medicines Agency (EMA) for the investigational drug depemokimab.
Key Financial Metrics
This filing is a regulatory update regarding clinical trial results and regulatory progress. It does not contain financial statements, revenue figures, profit margins, cash flow data, debt levels, or liquidity metrics.
Material Changes and Clinical Data
The filing details significant clinical milestones for depemokimab, an ultra-long-acting biologic targeting type 2 inflammation:
- Regulatory Status: The EMA's CHMP has recommended approval for depemokimab in two indications: severe asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps (CRSwNP). Final European Commission approval is expected in Q1 2026.
- Dosing Regimen: The drug is designed for a twice-yearly dosing schedule, distinguishing it as a potential first-in-class ultra-long-acting biologic in the EU for these respiratory diseases.
- Asthma Trial Results (SWIFT): Pooled data showed a 54% reduction in clinically significant exacerbations (rate ratio 0.46) and a 72% reduction in exacerbations requiring hospitalization or emergency visits compared to placebo.
- CRSwNP Trial Results (ANCHOR): Pooled data demonstrated statistically significant improvements in nasal polyp scores and nasal obstruction scales at 52 weeks.
- Safety Profile: The drug was well-tolerated across trials with side effect rates and severity similar to placebo.
Outlook, Risks, and Management Commentary
Management Commentary: Kaivan Khavandi, SVP & Global Head of Respiratory, Immunology & Inflammation R&D, stated that depemokimab could redefine care for millions by offering durable control with reduced treatment burden, addressing the needs of patients facing frequent exacerbations and chronic oral corticosteroid exposure.
Outlook: GSK anticipates a European Commission decision on approval in the first quarter of 2026. The drug is currently not approved anywhere in the world.
Risks and Contingencies: The filing includes a standard cautionary statement regarding forward-looking statements. Actual results may differ materially due to risks described in GSK's 2024 Form 20-F and Q3 2025 results, including regulatory approval uncertainties and clinical trial outcomes.
Key Facts for Investor Verification
- Verify the timeline for the final European Commission approval decision (expected Q1 2026).
- Confirm the commercial launch strategy and potential market size for depemokimab in the EU for severe asthma and CRSwNP.
- Monitor upcoming regulatory submissions in other major markets (e.g., FDA in the US) as the drug is currently unapproved globally.
- Review the full safety data from the SWIFT and ANCHOR trials to assess long-term tolerability.
- Check for any updates on the drug's pricing strategy and reimbursement negotiations with European payers.